Chronic plaque psoriasis
Drug research and approvals for chronic plaque psoriasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 8 studies of chronic plaque psoriasis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 13 drug trials for it since 2013.
- Recruiting worldwide: 8
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗- An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail PsoriasisNCT07725822 · Phase 4 · Modern Research Associates, PLLC · starts Sep 15, 2026
- Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque PsoriasisNCT07844772 · Not reported · Istanbul Training and Research Hospital · starts Jun 11, 2026
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisNCT07362017 · Phase 3 · Vanda Pharmaceuticals · starts Feb 17, 2026
- To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis…NCT07337434 · Early Phase 1 · Syeda Sana Zaman · starts Dec 25, 2025
- Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque PsoriasisNCT07261306 · Early Phase 1 · Lahore General Hospital · starts Aug 29, 2025
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)NCT07021495 · Not reported · Leiden University Medical Center · starts Jul 29, 2025
- Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?NCT06742333 · Phase 2 · Centre Hospitalier Universitaire de Nice · starts Jul 22, 2025
- Collection of Samples From Subjects With Various Skin Conditions and Healthy VolunteersNCT05994976 · Not reported · Innovaderm Research Inc. · starts Oct 17, 2023
Trials Authorized in Canada
The 10 newest of 13; search them all in Canada trials| Dec 20, 2019 | A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of arq-151 cream 0.3% administered qd in subjects with…ARQ-151 (ROFLUMILAST) | Arcutis Biotherapeutics | Closed |
| Oct 30, 2019 | Multicenter, randomized, parallel-group, double-blind, placiebo-controlled (12-17 years) including a single open-label arm (6-11 years) study to evaluate the…CIMZIA (CERTOLIZUMAB PEGOL) | UCB | Ongoing |
| Apr 3, 2019 | A multicenter, randomized, open-label study to evaluate the safe and effective use of the prefilled safety syringes or the auto-injector for the subcutaneous…BIMEKIZUMAB | UCB CANADA INC | Ongoing |
| Sep 4, 2018 | A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumb in adult subjects with moderate to severe chronic…BIMEKIZUMAB | UCB | Closed |
| Jul 11, 2018 | A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and…NANOBODY ANTI IL 17A/F (MSB0010841 OR M1095 OR ALX0761) | BOND AVILLION 2 DEVELOPMENT LP | Closed |
| Jun 28, 2018 | A phase 3, multicenter, randomized, placebo- and active comparator-controlled study evaluating the efficacy, safety, and pharmacokinetics of subcutaneously…TREMFYA | Johnson & Johnson | Ongoing |
| Jun 12, 2018 | A multicenter, randomized, double-blind, secukinuimab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects…BIMEKIZUMAB (UCB4940) | UCB | Ongoing |
| Jun 8, 2018 | A randomized, double-blind, placebo and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placeboand…COSENTYX | Novartis Pharmaceuticals Corporation | Closed |
| Mar 10, 2017 | A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to…BIMEKIZUMAB | UCB | Closed |
| Nov 9, 2016 | A multicenter, randomized, subject-blind, investigator-blind study to evaluate the time course of pharmacodynamic response, safety and pharmacokinetics of…UCB4940 (BIMEKIZUMAB) | UCB | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA